Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 3.17 USD 6.38% Market Closed
Market Cap: 757.8m USD

Net Margin

-34.8%
Current
Improving
by 89.4%
vs 3-y average of -124.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-34.8%
=
Net Income
$-105.8m
/
Revenue
$303.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-34.8%
=
Net Income
$-105.8m
/
Revenue
$303.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
Esperion Therapeutics Inc
NASDAQ:ESPR
757.8m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.4B USD
Loading...

Market Distribution

Lower than 79% of companies in the United States of America
Percentile
21st
Based on 15 072 companies
21st percentile
-34.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Esperion Therapeutics Inc
Glance View

Esperion Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Ann Arbor, Michigan and currently employs 218 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

ESPR Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-34.8%
=
Net Income
$-105.8m
/
Revenue
$303.8m
What is Esperion Therapeutics Inc's current Net Margin?

The current Net Margin for Esperion Therapeutics Inc is -34.8%, which is above its 3-year median of -124.2%.

How has Net Margin changed over time?

Over the last 3 years, Esperion Therapeutics Inc’s Net Margin has increased from -337.8% to -34.8%. During this period, it reached a low of -337.8% on Sep 30, 2022 and a high of -15.6% on Dec 31, 2024.

Back to Top